Rahul Aggarwal, MD

Education

Northwestern University, Evanston, IL, BA, 1999-2002, Psychology
Northwestern University Feinberg School of Medicine, Chicago, IL, MD, 2002-2006, Medicine

Honors & Awards

• 2001
  James Alton James Scholarship, Northwestern University
• 2002
  James A. Patten Scholarship, Northwestern University
• 2002
  Phi Beta Kappa Centennial Award, Northwestern University
• 2002
  Summa Cum Laude, Northwestern University
• 2004
  Department of Medicine Chairman’s Award, Northwestern University School of Medicine
• 2005
  Member Alpha Omega Alpha medical honor society
• 2011
  Pfizer Fellowships in Oncology Award in collaboration with UCSF Division of Hematology/Oncology, Department of Medicine
• 2012
  Young Investigator Award, American Society of Clinical Oncology/Conquer Cancer Foundation
• 2012
  Inaugural Recipient, Ronald A. Rosenberg Fellowship in Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center
• 2013
  Alliance Cooperative Group Scholar Award
• 2014
  The Sence Foundation Award
• 2015
  Prostate Cancer Foundation Young Investigator Award
• 2016
  Department of Defense Prostate Cancer Research Program Physician Research Training Award
• 2016
  UCSF Helen Diller Family Early Phase Clinical Research Support Grant
• 2016
  National Cancer Institute Cancer Clinical Investigator Team Leadership Award

Selected Publications

1. Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.  View on PubMed
2. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS Differential Treatment Outcomes in BRCA1/2-, CDK12-, and ATM-Mutated Metastatic Castration-Resistant Prostate Cancer.  View on PubMed
3. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.  View on PubMed
4. Sun J, Bok RA, DeLos Santos J, Upadhyay D, DeLos Santos R, Agarwal S, Van Criekinge M, Vigneron DB, Aggarwal R, Peehl DM, Kurhanewicz J, Sriram R Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models.  View on PubMed
5. Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.  View on PubMed
6. Chen W, Mou KY, Solomon P, Aggarwal R, Leung KK, Wells JA Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy.  View on PubMed
7. Kwon DH, Aggarwal RR, Esserman LJ, Belkora JK Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era.  View on PubMed
8. Wang S, Li J, Hua J, Su Y, Beckford Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J Molecular imaging of prostate cancer targeting CD46 using immunoPET.  View on PubMed
9. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY Autoantibody Landscape in Patients with Advanced Prostate Cancer.  View on PubMed
10. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Ruiz DG, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ The synthesis and structural requirements for measuring glucocorticoid receptor expression in vivo with (±)-11C-YJH08 PET.  View on PubMed
11. Han HJ, Li YR, Roach M, Aggarwal R Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.  View on PubMed
12. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.  View on PubMed
13. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.  View on PubMed
14. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY The DNA methylation landscape of advanced prostate cancer.  View on PubMed
15. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.  View on PubMed
16. Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, Pérez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.  View on PubMed
17. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.  View on PubMed
18. Carneiro BA, Lotan TL, de Souza A, Aggarwal R Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer.  View on PubMed
19. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography.  View on PubMed
20. Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.  View on PubMed

Go to UCSF Profiles, powered by CTSI